Home›NAPLEX›NAPLEX Oncology Review 2026
🏥 NAPLEX Oncology — Chemo Safety & Supportive Care — 2026

NAPLEX Oncology Review 2026

Chemotherapy safety, supportive care, antiemetic regimens, growth factors, hazardous drug handling — key oncology concepts for the NAPLEX with counseling points and practice links.

NAPLEX Oncology — What You Need to Know

The NAPLEX does not test detailed oncology regimen selection in depth, but it does heavily test supportive care (antiemetics, growth factors, tumor lysis syndrome prevention), hazardous drug handling (USP 800), and chemotherapy safety protocols. These are the high-yield areas to focus on.

Antiemetic Regimens by Emetogenic Risk

Emetogenic RiskAntiemetic RegimenExamples of Chemo
High (>90%)NK1 antagonist + 5-HT3 antagonist + dexamethasone ± olanzapineCisplatin, AC (doxorubicin + cyclophosphamide)
Moderate (30-90%)5-HT3 antagonist + dexamethasone ± NK1 antagonistCarboplatin, irinotecan, oxaliplatin
Low (10-30%)Dexamethasone or 5-HT3 antagonistFluorouracil, paclitaxel, docetaxel
Minimal (<10%)No routine prophylaxisBevacizumab, rituximab, bleomycin

Key drug names: NK1 antagonists: aprepitant/fosaprepitant, netupitant. 5-HT3 antagonists: ondansetron, granisetron, palonosetron (longest acting). Olanzapine 5-10mg added for highly emetogenic regimens per ASCO/NCCN guidelines.

Growth Factors — Neutropenia Management

  • Filgrastim (G-CSF): Stimulates neutrophil production. Given 24-72 hours AFTER chemo (never same day). For regimens with >20% febrile neutropenia risk.
  • Pegfilgrastim: Long-acting filgrastim. Single dose per chemo cycle. Must be given ≥24 hours after AND ≥14 days before next cycle.
  • Storage: Refrigerate (2-8°C). Do not shake. Discard if left at room temperature >24 hours (filgrastim) or >48 hours (pegfilgrastim).

Hazardous Drug Handling (USP 800)

USP 800 requires: antineoplastic HD compounding in a C-PEC (Class II BSC or CACI) within a negative-pressure room (≥12 ACPH). Double gloving, closed-system transfer devices (CSTDs) where available, and decontamination/deactivation procedures. Applies to ALL entities that handle hazardous drugs — not just hospital pharmacies.

Tumor Lysis Syndrome (TLS) Prevention

  • Allopurinol: Prevents uric acid formation. Given prophylactically before chemo for moderate TLS risk.
  • Rasburicase: Converts uric acid to allantoin. For high TLS risk or established hyperuricemia. CI in G6PD deficiency (hemolytic anemia risk).
  • Aggressive IV hydration: NS to maintain urine output. Electrolyte monitoring (K+, PO4, Ca2+, uric acid).
Compounding Law Quiz (USP 800) → ← ID Review Cardiology Review

Practice Oncology & Supportive Care Questions

PharmacyExam.com covers chemo safety, antiemetics, and supportive care with NAPLEX-style questions.

Explore PharmacyExam →
← NAPLEX HubPractice QuestionsStudy Guide